Drugs / Cosibelimab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06981806 | Jan 2026 → Feb 2027 expected | pancreatic ductal adenocarcinoma | Arsen Osipov | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03778073 | Apr 2019 → May 2022 | B-cell non-Hodgkin lymphoma, Richter transformation | TG Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03212404 | Sep 2017 → Nov 2021 overdue | classic Hodgkin lymphoma, cutaneous neuroendocrine carcinoma, endometrial cancer, head and neck cancer +8 | Checkpoint Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02535286 | Sep 2015 → Nov 2021 | Richter transformation, chronic lymphocytic leukemia/small lymphocytic lymphoma | TG Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04786964 | Dec 2021 → Dec 2023 | non-small cell lung carcinoma | Checkpoint Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT07426484 | Jul 2026 → Dec 2030 expected | skin squamous cell carcinoma | Dana-Farber Cancer Institute | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl) sunpharma.com ↗
Patients received a median of 29 doses over a median treatment duration of 60 weeks. |
| 2025-11-26 | Sun Pharmaceutical Industries, Inc. | Regulatory FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC) sunpharma.com ↗
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC) |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-26 | Sun Pharmaceutical Industries, Inc. | Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl) sunpharma.com ↗ |
| 2026-01-15 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) sunpharma.com ↗ |
| 2025-11-26 | Sun Pharmaceutical Industries, Inc. | FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC) sunpharma.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cosibelimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03212404 ↗ |
| Known as | CK-301 | “A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy” NCT04786964 ↗1“CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype” NCT03212404 ↗ |
| Known as | Cosibelimab-ipdl | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297729 ↗ |
| Known as | TG-1501 | “A Phase 1 Study of Cosibelimab (TG-1501) in Subjects With Relapsed or Refractory Lymphoma” NCT03778073 ↗ |
| Known as | Unloxcyt | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297729 ↗ |
| Action | Inhibit | “Cosibelimab is a high-affinity programmed cell death-ligand 1 (PD-L1)-blocking antibody” PMID 37848259 ↗ Oct 20231“Programmed cell death 1 ligand 1 inhibitor” CHEMBL4297729 ↗ |
| Modality | Monoclonal antibody | “a fully human monoclonal antibody of IgG1 subtype” NCT03212404 ↗ |
| Route | Intravenous | “IV immunotherapy for cancer” NCT02535286 ↗ |
| Target | CD274 | “Programmed cell death 1 ligand 1 inhibitor” CHEMBL4297729 ↗ |